Navigation Links
Monotherapy BYETTA(R) (exenatide) Injection Study Results Presented at ADA 2008 Showed Adults with Type 2 Diabetes Experienced Improved Glycemic Control and Weight Loss
Date:6/7/2008

therapies to help healthcare professionals improve the lives of people with diabetes, and research continues on innovative medicines to address the unmet needs of patients. For more information about Lilly's current diabetes products visit, http://www.lillydiabetes.com.

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of first-in-class and best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Indiana, Lilly provides answers - through medicines and information - for some of the world's most urgent medical needs. Additional information about Lilly is available at http://www.lilly.com.

This press release contains forward-looking statements about Amylin and Lilly. Actual results could differ materially from those discussed or implied in this press release due to a number of risks and uncertainties, including the risk that BYETTA and the revenues generated from BYETTA may be affected by competition; unexpected new data; technical issue; clinical trials not confirming previous results; pre-clinical trials not predicting future results; label expansion requests, including the FDA submission referred to in this press release, not being submitted in a timely manner or receiving regulatory approval; or manufacturing and supply issues. The potential for BYETTA may also be affected by government and commercial reimbursement and pricing decisions, the pace of market acceptance, or scientific, regulatory and other issues and risks inherent in the commercialization of pharmaceutical products. These and additional risks and uncertainties are described more fully in Amylin and Lilly's most recently filed SEC including their Quarterly Reports on Form 10-Q and Annual Reports on Form 10-K. A
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. TARGETED GENE DELIVERY IN VIVO: Rexin-G Monotherapy Reveals Significant Biological Activity Without Toxicity in Chemo-Resistant Metastatic Breast Cancer (ASCO 2008)
2. Roche and Pharmasset To Present the R7128 Monotherapy Resistance Profile
3. Multiple Clinical Trials of VELCADE(R) (Bortezomib) for Injection Based Therapies Demonstrate High Complete Remission Rates in Patients with Newly Diagnosed Multiple Myeloma
4. VELCADE(R) (Bortezomib) for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Multiple Myeloma
5. New Eloxatin(R) (oxaliplatin injection) Prescribing Information in the U.S. Includes Six-Year Overall Survival Data
6. Ikaria Completes Dosing of Phase 1a Clinical Study for IK-1001 (Sodium Sulfide) for Injection
7. New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma
8. Patients Treated with Risperidone Long-Acting Injection had a Significantly Longer Time to Relapse Compared to Quetiapine in International Clinical Study
9. CorMatrix(R) Announces Intramyocardial Injection of Emulsified ECM Technology(TM) Demonstrates Enhanced Angiogenesis and Improved Cardiac Function in a Preclinical Model
10. Circulation Publishes Data Showing KYNAPID(TM) (Vernakalant Hydrochloride) Injection Rapidly Converted Short-Duration Atrial Fibrillation to Sinus Rhythm
11. Inclusion of Six-Year Overall Survival Data in the Eloxatin(R) (oxaliplatin injection) Prescribing Information Granted FDA Priority Review
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... EVANSVILLE, Ind. , Sept. 16, 2014   ... builder of custom, automated assembly and test systems, recently ... for a leading medical device manufacturer. The Evana solution ... improve quality and ergonomics, as well as reduce labor. ... are automatically fed to Evana,s robotic assembly cell. The ...
(Date:9/16/2014)... 16, 2014   Vestagen Technical Textiles, Inc. ... at hospitals. The myComfort™ line of patient apparel is ... that is fluid repellant, breathable and in studies done ... of bacteria on the fabric i . ... the chain of transmission. We want myComfort to be ...
(Date:9/16/2014)... 16, 2014  Synereca Pharmaceutics, Inc. (SPI), ... active drugs that restore or increase the ... $1.4 million convertible debt financing. Accele Venture ... accelerator Accele Biopharma, Inc., led the financing ... recognized private not-for-profit corporation focused on growing ...
Breaking Medicine Technology:Evana Automation to Supply Robotic Assembly Cell to Leading Medical Device Manufacturer 2Evana Automation to Supply Robotic Assembly Cell to Leading Medical Device Manufacturer 3New Vestagen Patient Garments Aim to Minimize Pathogen Transmission Inside Hospitals 2Synereca Pharmaceuticals Announces Financing Led by Accele Venture Partners 2Synereca Pharmaceuticals Announces Financing Led by Accele Venture Partners 3Synereca Pharmaceuticals Announces Financing Led by Accele Venture Partners 4
... Council (NPC) today welcomed global specialty biopharmaceutical company Shire ... senior vice president, specialty pharma R&D, will serve as ... "The last few years have brought change ... important questions unresolved.  For the pharmaceutical industry, how ...
... Medical, Inc., a Minnesota-based medical device company, has announced that ... eripheral F acilitated A ntegrade S teering ... O cclusions (PFAST-CTOs) study.  The company received approval from ... US based IDE for the peripheral devices and is now ...
Cached Medicine Technology:National Pharmaceutical Council Welcomes Shire as Its Newest Member 2BridgePoint Medical Announces US IDE Approval and First Patient Enrollment of Peripheral Chronic Total Occlusion Study 2
(Date:9/16/2014)... iFitDress.com, one of the most famous dress suppliers in the ... collection. According to the company’s sales manager, all these ... 69% off) at present. Additionally, all the company’s old clients ... frequent caller of your site. I like your products very ... happy. All items are of good quality. I sincerely want ...
(Date:9/16/2014)... HealthDay Reporter TUESDAY, Sept. ... routinely spot human papillomavirus (HPV), which is linked to the ... study shows that testing urine for HPV has good accuracy ... HPV," said lead researcher Dr. Neha Pathak. She is a ... Mary University of London, England. The test could be ...
(Date:9/16/2014)... September 16, 2014 These new programs allow ... years to receive up to $10,000 in a 0% interest ... well as other state and federal programs, are listed on ... paid back until you sell or move out of the ... 0% interest loan. There are no monthly payments paid by ...
(Date:9/16/2014)... A new study found that fractional flow ... true coronary bifurcation lesions yields similar outcomes to ... trial is the first study to compare FFR-guided ... today at the 26th annual Transcatheter Cardiovascular Therapeutics ... Foundation (CRF), TCT is the world,s premier educational ...
(Date:9/16/2014)... September 16, 2014 Programs and policies ... hundreds of billions of dollars in savings for the ... the Commonwealth Fund. To help spur these types of ... to 10 collaborative groups from across the country to ... http://bit.ly/1wo4gsa ) - a handbook designed to assist groups ...
Breaking Medicine News(10 mins):Health News:iFitDress.com: One Shoulder Evening Gown Collection Unveiled Online 2Health News:Urine Test for HPV Works Well, Analysis Finds 2Health News:New Updated 2014 First Time Home Buyer Programs Available to Florida Residents 2Health News:New Updated 2014 First Time Home Buyer Programs Available to Florida Residents 3Health News:Results of DKCRUSH-VI trial reported at TCT 2014 2Health News:NQF Seeks Field Testing Groups for Population Health Guide 2Health News:NQF Seeks Field Testing Groups for Population Health Guide 3
... Cancer (CoC) of the American College of Surgeons has granted ... Cancer Center as a result of surveys performed in 2010. ... to receive this award, is one of a select group ... country. Established in 2004, the CoC Outstanding Achievement ...
... , TUESDAY, April 26 (HealthDay News) -- The increased use ... and rapid angioplasty, has led to a decrease in deaths, ... a Swedish coronary care registry on more than 61,000 patients ... known as STEMI between 1996 and 2007. During those ...
... Sheikh Zayed Institute for Pediatric Surgical Innovation at ,Children,s ... has shown early promise as an option for chronic, severe ... bacterial infections, particularly sepsis. The study, which appears ... , sheds new light on the role of a pain ...
... for publication in The Endocrine Society,s Journal of Clinical ... white children with vitamin D deficiency both had higher fat ... of fat just under their skin and white children were ... internal organs. Studies in adults and children have shown ...
... needs a national pharmacare program and federal leaders must ... ( Canadian Medical Association Journal ) http://www.cmaj.ca/cgi/doi/10.1503/cmaj.110643 ... and New Zealand, Canada lacks a national pharmacare program ... country. Currently, drugs that are covered in some provinces ...
... HealthDay Reporter , TUESDAY, April 26 (HealthDay News) -- ... the risk of developing Alzheimer,s disease, a new study ... to the house causes dementia, and other factors could ... the possible cost of isolation, said lead investigator Bryan ...
Cached Medicine News:Health News:Scott & White Glenda Vasicek Cancer Center receives national achievement award 2Health News:Evidence-Based Heart Attack Care Reduces Deaths: Study 2Health News:Evidence-Based Heart Attack Care Reduces Deaths: Study 3Health News:Study: Resiniferatoxin may increase sepsis-related mortality 2Health News:Vitamin D deficiency is associated with different types of obesity in black and white children 2Health News:Canadians should demand commitments for pharmacare program, says CMAJ 2Health News:Being 'Housebound' Linked to Alzheimer's in Elderly 2Health News:Being 'Housebound' Linked to Alzheimer's in Elderly 3
The K-ASSAY® D-Dimer Control set is intended to be used a consistent test sample of known concentration for monitoring the performance of D-Dimer immunoturbidimetric assays....
Microalbumin Linearity Control...
Total IgE Control...
The K-ASSAY Lipid Controls are assayed controls produced from fresh human sera to monitor the accuracy and precision of quantitative lipid determinations of human sera specimens....
Medicine Products: